Aquestive Therapeutics, Inc. announced the appointments of Timothy E. Morris to the Company's Board of Directors, effective August 5, 2022, and Kenneth Truitt, M.D., as Chief Medical Officer effective September 6, 2022.   Aquestive's Board of Directors will now be comprised of seven Directors, six of whom are independent directors.   Mr. Morris has been appointed to the Audit Committee of the Board of Directors. Mr. Morris presently serves as the Chief Operating Officer and Chief Financial Officer of Humanigen, Inc., where he focuses his attention on manufacturing, supply chain, corporate development, human resources, finance, investor relations, and public relations. Previously he served as the Chief Financial Officer of Iovance Biotherapeutics, Inc. from 2017 to 2020, AcelRx Pharmaceuticals, Inc. from 2014 to 2017, and Vivus Inc. from 2004 to 2013.

Mr. Morris has extensive Board experience, currently serving as a board member of DBV Technologies, where he is a members of the audit and pricing committees, Univercells S.A., where he is a member of the audit and strategic committees, Humanetics Corporation, where he serves as the chair of the audit committee and a member of the compensation committee, and Humanigen Australia PTY Ltd, Humanigen Ltd., and Humanigen EU Ltd.Mr. Morris previously served on the boards of directors of Humanigen, Inc. from 2016 to 2020, and PAION, Inc., a U.S. subsidiary of PAION AG. Mr. Morris earned a BS in Business, with an emphasis in Accounting, from California State University and is a Certified Public Accountant.   Upon joining the Audit Committee, the Company's Chairman of the Board, Mr. Santo J. Costa, will be stepping down as a member of the Audit Committee. Dr. Truitt previously served as Chief Medical Officer at Venthera Inc. and ImmusanT Inc.Dr. Truitt has garnered experience in clinical development, spanning pre-IND through registration across multiple therapeutic areas and has extensive experience with autoimmunity and inflammation, CNS and sensory, pain/analgesia, pulmonary, and rare diseases.

He received his post-graduate medical training in internal medicine and rheumatology from the University of California at San Francisco.